Introduction: The Evolution of Evidence and a New Source of Value
The clinical research and drug development ecosystem has long relied on the high-standard evidence (efficacy) provided by Randomized Controlled Trials (RCTs). However, the limited populations, strict inclusion/exclusion criteria, and controlled treatment environments of RCTs paint an incomplete picture of a drug's real-world effectiveness and usability.
It is at this juncture that Real-World Evidence (RWE) has taken the stage. Using data collected from Electronic Health Records (EHR), patient files, and insurance databases, the gaps left by traditional research are being filled. Yet to unlock the full potential of RWE, it is necessary to incorporate the patient's direct experience into these large datasets. This becomes possible through the strategic integration of Patient-Reported Outcomes (PROs).
PROs are measurements that reflect patients' direct perceptions of their own health status, symptoms, and treatment effects, without the need for any medical professional interpretation. When the broad scope of RWE is combined with the depth of PROs, a powerful, holistic evidence standard emerges that fundamentally transforms decision-making processes for regulators, payers, and healthcare providers.
1. Real-World Evidence (RWE) and the Limitations of Traditional Data
From RCTs to Reality
While traditional Phase 3 RCTs demonstrate whether a drug works under optimal conditions, they fail to adequately account for the following real-world realities of patients:
- Patients with multiple comorbidities
- Patients struggling to adhere to complex medication regimens
- Patients with social and economic disparities
- Patients using medications long-term in real-world settings
RWE is designed to address these shortcomings. Data collected across large, heterogeneous populations provides comprehensive information about the real-world performance of a drug or treatment.
Critical Gaps in RWD
However, Real-World Data (RWD), by its very nature, carries significant gaps regarding the patient's subjective experience:
Symptom Severity An EHR record shows when a patient visited the hospital, but does it capture the severity and persistence of pain, fatigue, or nausea experienced at home? No.
Quality of Life (QoL) Changes in a patient's quality of life following treatment (sleep patterns, participation in social activities, daily functioning) are not recorded in traditional medical records.
Treatment Adherence and Persistence Whether the patient takes the prescription regularly or how long they continue the treatment regimen remains largely unclear.
Subjective Adverse Effects Mild or moderate side effects (headache, stomach discomfort, loss of energy) may be forgotten or dismissed during a physician consultation.
The only reliable source that fills these gaps is the patient themselves -- that is, PROs.
2. PROs: The Direct Transformation of the Patient's Voice into Evidence
What Is a PRO and Why Does It Matter?
A PRO (Patient-Reported Outcome) is a measurement of the patient's direct perception regarding their health status, symptoms, and functional capacity related to their disease or treatment. PROs quantitatively capture the impact of a medication on a patient's daily life, mood, and overall well-being.
ePRO (electronic PRO) enables real-time, automated data collection through mobile applications or web interfaces.
The Critical Role of PROs in RWE Studies
1. Humanized Evidence
Regulators (FDA, EMA) and payers want to see beyond a drug's improvement of biological markers -- they want to understand how the drug changes the patient's life. PRO data presents the clinical benefit of a treatment from the patient's perspective and plays a critical role in regulatory decision-making.
2. Data Integrity and Real-Time Collection
Especially in chronic diseases, symptoms experienced between hospital visits are frequently forgotten or inaccurately recalled (recall bias). Through ePRO platforms, data is collected immediately after the event, minimizing recall errors.
3. In-Depth Analysis of Heterogeneous Populations
RWE studies may involve hundreds of thousands of patients. PRO data adds a critical analytical layer to this broad population, enabling the understanding of which demographic groups or patients with comorbidities derive greater benefit from treatment, and in which subgroups side effects are more frequent.
3. PRO and RWE Synergy: Transformation Across the Value Chain
Measuring Treatment Adherence and Persistence
The success of RWE studies is directly tied to how long patients continue treatment (persistence) and how regularly they use it (adherence).
Traditional RWD Problem: Pharmacy records may show that medications were purchased, but they do not confirm whether the patient actually took them. Hospital visits, being infrequent, cannot cover the time in between.
PRO Solution: Through digital PRO platforms:
- Patients can confirm medication intake via a mobile application
- The system sends visit reminders, reducing dropout rates at hospital appointments
- Patient-reported side effects reveal the factors influencing the decision to continue treatment
Data Quality and Verifiability
Ensuring data reliability when integrating PRO data into RWE is a critical challenge. Modern solutions include:
Identity Verification (KYC) Verifying the patient's identity through national health systems guarantees that the collected PRO data comes from a real and traceable source. This exponentially increases the reliability and acceptability of the data for regulators.
Medication History Verification Symptom and adverse event data collected via PROs are cross-checked against the patient's historical comorbidities and concomitant medications. This minimizes the risk of bias and is only possible through digital integration.
Temporal Consistency As the data collection frequency (in days) increases, the accuracy and value of the data improve. Daily ePRO alerts, as opposed to monthly questionnaires, significantly reduce patients' recall bias.
The Impact of PROs on Strategic Decision-Making
PRO-enhanced RWE data directly influences the decision-making processes of pharmaceutical companies and payers:
Market Access and Reimbursement Decisions
Payers (reimbursement bodies) want to see beyond a drug's clinical efficacy -- they want to understand how much the drug improves the patient's quality of life. PRO data provides an indispensable argument for drug pricing and reimbursement coverage decisions.
Pharmacovigilance and Safety
After a drug is launched (Post-Marketing Surveillance), rare or under-reported side effects that patients may not consider significant can be rapidly collected through PRO tools.
Labeling and Claims
PRO data can provide strong evidence for adding new claims to a drug's packaging label, such as "Improves Quality of Life" or "Reduces Pain by X%."
4. The Turp Application: Practical Implementation of PRO and RWE Integration
What Is Turp? An Integrated Digital Ecosystem
Turp is a comprehensive mobile application designed for clinical research professionals, CROs, and sponsors, combining ePRO collection, patient management, and health system integration. Turp provides the technological infrastructure that enables PROs to be used effectively in RWE studies.
Core Features of Turp and Their Contributions to RWE
1. e-Nabiz Integration: Verification and Integrity
Connection to Turkey's National Health Information System
Turp operates in direct integration with e-Nabiz (National Health Informatics Portal) and MHRS (Central Physician Appointment System). This integration provides the following critical benefits:
-
Identity Verification (KYC): The patient logs into the Turp application with their identity verified through e-Nabiz. This 100% guarantees that the PRO data comes from a real and traceable source.
-
Automatic Medication History Retrieval: The patient's complete pharmacy and hospital prescription history is automatically loaded into Turp. Symptom data collected via PROs is automatically cross-checked against this medication history. In this way, the medication associated with an adverse event report can be algorithmically determined.
-
Comorbidity and Health Status Profile: The patient's chronic conditions (hypertension, diabetes, etc.) are automatically retrieved from e-Nabiz. During RWE analysis, this data can be used for subgroup analyses.
-
Data Validation and Consistency: PRO data collected through Turp is automatically cross-checked against medical records in e-Nabiz. This enables the detection of data bias and inconsistencies.
2. Smart Reminder System: Maximizing Adherence and Persistence
Problem: In traditional RWE studies, patients forget or neglect questionnaires. This leads to insufficient data collection and selection bias.
Turp's Solution: Turp employs an AI-powered, personalized reminder system:
-
Optimal Scheduling: Reminders are sent at the most appropriate time by considering factors such as the hours the patient most frequently uses their phone and medication intake times.
-
Multi-Channel Communication: Reminders are delivered through various channels including SMS, push notifications, and email. Patients can choose their preferred channel.
-
In-App Response: The reminder directs the patient directly to the mobile application. Patients can easily complete questionnaires through the app without needing to open a browser or take additional steps.
-
Data Visualization: The application shows patients their previous responses, ensuring data consistency and reducing redundant recall.
Effectiveness: In studies using Turp, questionnaire completion rates reach 85%, whereas traditional paper-based methods remain below 40%.
3. Structured PRO Questionnaires: Data Quality
Turp's Questionnaire Architecture:
- Ready-Made Library: FDA-approved, validated PRO instruments (such as PROMIS, SF-36, EQ-5D) are available as ready-to-use templates in Turp.
- Conditional Questions: Subsequent questions dynamically change based on the patient's previous responses. Unnecessary questions are avoided.
- Logic Checks: Range checks and consistency validations are performed automatically. Erroneous data entries are rejected immediately.
- Multi-Language Support: Questionnaires are presented in Turkish, English, Kurdish, and other languages.
4. Real-Time Data Analytics: For Sponsors and CROs
Turp's Dashboard Capabilities:
-
Live PRO Data Repository: Sponsors and CROs can view collected PRO data in real time throughout the research process.
-
Abnormal Value Alerts: Serious adverse events or emergencies reported by the patient (severe pain, intense dizziness, etc.) are automatically detected and alerts are sent to the research team.
-
Adherence Tracking: Each patient's questionnaire completion frequency, missed questionnaires, and compliance status can be viewed on the dashboard.
-
Cohort Analysis: Subgroup analyses (by age, gender, comorbidities) are performed automatically and results are visualized.
5. Patient-Centric Design: Usability and Patient Satisfaction
- Intuitive Interface: Even elderly patients can use the application with minimal training.
- Voice Option: Patients with low literacy can listen to questions and respond verbally.
- Gamification: Patients who complete questionnaires earn points, which can be redeemed for health goals.
- Progress Indicators: Patients can view their own health trajectory, which increases motivation.
5. Tangible Outcomes of RWE + PRO Integration with Turp
Data Quality Improvements
| Metric | Before Turp | After Turp | Improvement |
|---|---|---|---|
| Questionnaire Completion Rate | 40% | 85% | +112% |
| Data Usability | 70% | 98% | +40% |
| Data Entry Errors | 8-12% | <1% | -90% |
| Database Lock Time | 6-8 weeks | 1-2 weeks | -75% |
| Patient Satisfaction | 5.2/10 | 8.1/10 | +55% |
Research Output Effectiveness
- Bias Reduction: Thanks to e-Nabiz integration, selection bias and recall bias have been significantly reduced.
- Subgroup Analysis: Automatic medication and comorbidity data enable more reliable subgroup analyses.
- Audit-Ready Data: In FDA and EMA inspections, Turp's system logs and identity verification records are presented as evidence of data integrity.
- Rapid Insight: The real-time dashboard enables early detection of anomalies during the research process.
6. Regulatory Acceptability
FDA and EMA's Perspective on Turp-Supported PRO Data
- 21 CFR Part 11 Compliance: Turp complies with the robustness standards required by the FDA for electronic records (21 CFR Part 11).
- Data Integrity Trails: Turp records who made each data entry and when. These trails serve as evidence of data reliability during regulatory inspections.
- Pre-Specified Analytical Plan: PRO data collected through Turp is structured to be compliant with CDISC standards (SDTM, ADaM).
7. Conclusion: With Turp, PRO and RWE Are the New Assurance of Research
Clinical research professionals -- sponsors, CROs, and investigators -- can now recognize that PRO-enhanced RWE is not merely a goal but a reality.
The Turp application makes this transformation possible:
- e-Nabiz Integration: Ensures data reliability and regulatory acceptability
- Smart Reminders: Maximizes adherence and data completion rates
- Structured Questionnaires: Enhances data quality and usability
- Real-Time Analytics: Makes the research process more controlled and efficient
- Patient-Centric Design: Improves patient satisfaction and engagement
The Future of PROs
Through integrated digital platforms like Turp:
- The Regulatory Landscape Is Shifting: FDA and EMA now accept PRO data with as much weight as RCT outcomes.
- Market Access Is Accelerating: PRO-enhanced RWE evidence expedites reimbursement decisions by payers.
- Research Costs Are Declining: As data quality improves, analysis efforts decrease and projects conclude more rapidly.
- Patient Engagement Is Increasing: User-friendly platforms like Turp encourage greater patient participation in research.
In conclusion, Turp elevates PROs from a mere "supplement" to traditional data into a fundamental component of research design. This has opened the door to a patient-centered, evidence-based, and humanized research paradigm.